Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years-Reference-Cited by-同舟云学术

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Published:2020 Issue:1 Volume:19 Page:15
ISSN:1450-1147
Container-title:World Journal of Nuclear Medicine
language:en
Short-container-title:World J Nucl Med

Author:

Assadi Majid,Rezaei Samira,Jafari Esmail,Rekabpour SeyedJavad,Ravanbod MohammadReza,Zohrabi Farshad,Amini AbdulLatif,Keshmiri Saeid,Dadgar Habibollah,Ahmadzadehfar Hojjat

Publisher

Medknow

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Production of the state of the art therapeutic radiopharmaceuticals in Iran, from beta- to alpha-emitting targeted radionuclide therapy: Clinical advances and perspectives;IRAN J NUCL MED;2024

3. Genomic Discoveries: Precision Medicine and Personalized Approaches in Prostate Cancer Care;Transforming Prostate Cancer Care;2024

4. A convolutional neural network–based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-14

5. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT);European Journal of Nuclear Medicine and Molecular Imaging;2023-05-29